When was Tango Therapeutics founded?

Tango Therapeutics was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Tango Therapeutics located?

Tango Therapeutics is headquartered in Cambridge, United States.

How many employees does Tango Therapeutics have?

As of May 31, 2026, the latest employee count at Tango Therapeutics is 153.

Is Tango Therapeutics a funded company?

Tango Therapeutics is a funded company, having raised a total of $165M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 30, 2017.

When was the latest funding round of Tango Therapeutics?

Tango Therapeutics' latest funding was a $***** Post IPO round on Oct 24, 2025, with participation from 0 investor.

What is the annual revenue of Tango Therapeutics?

Annual revenue of Tango Therapeutics is between $50M and $100M as on Dec 31, 2025

Where does Tango Therapeutics rank among its competitors?

Tango Therapeutics ranks 20th amongst 3314 active competitors, of which 1142 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Tango Therapeutics, which secured $15M in Oct, 2025.

Who are the top competitors of Tango Therapeutics?

Tango Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Tango Therapeutics secured the most recent funding round in October, 2025.

Tango Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Tango Therapeutics is a public company based in Cambridge (United States), founded in 2017 by Levi Garraway and Tim Lu. It operates as a Developer of drugs for the treatment of cancer. Tango Therapeutics has raised $165M in funding from Casdin Capital and Boxer Capital. The company has 3314 active competitors, including 1142 funded and 780 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.

Website: www.tangotx.com/
Email ID: *****@tangotx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Public

Total Funding

$165M in 5 rounds

Latest Funding Round

Post IPO, Oct 24, 2025, $*****

Investors

Casdin Capital & 8 more

Ranked

20^th among 3314 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

153 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3083 more

Exit Details

Public

View Tango Therapeutics' full profile

Tango Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tango Therapeutics, Inc. CIN: 1819133 , United States, Active	May 20, 2020	$50M - $100M (As on Dec 31, 2025)	-	-
TANGO THERAPEUTICS, INC CIN: 472452488 , United States, Active		-	154 (As on Dec 31, 2024)	-

Tango Therapeutics got listed on Sep 04, 2020.

Click here to take a look at Tango Therapeutics's IPO in detail

Tango Therapeutics has raised a total funding of $165M over 5 rounds. Its first funding round was on Mar 30, 2017. Tango Therapeutics has 9 institutional investors.

Here is the list of recent funding rounds of Tango Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 24, 2025	4957164	Post IPO	9280595	8379384	1397829	3171200
Aug 10, 2023	1850347	Post IPO	8148326	7469686	7624935	3101746
Aug 17, 2020	7184848	Series B	8569475	9952828	Casdin Capital	Boxer Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Tango Therapeutics's funding rounds and investors

The founders of Tango Therapeutics are Levi Garraway and Tim Lu. Barbara Weber Md is the CEO of Tango Therapeutics.

Here are the details of Tango Therapeutics' key team members:

Levi Garraway: Co-Founder of Tango Therapeutics and founder of 1 other company.
Contact Info: 1 email address
Tim Lu: Co-Founder of Tango Therapeutics and founder of 1 other company.
Contact Info: 2 email addresses

View details of Tango Therapeutics's Founder profiles and Board Members

Tango Therapeutics' employee count trend

Tango Therapeutics has 153 employees as of May 26. Here is Tango Therapeutics's employee count trend over the years:

Employee count trend for Tango Therapeutics

Uncover Tango Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tango Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Tango Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
20th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Bain Capital Life Sciences ... & 7 others	71/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Tango Therapeutics's competitors? Click here to see the top ones

Tango Therapeutics has made no investments or acquisitions yet.

Media has covered Tango Therapeutics for a total of 20 events in the last 1 year, 11 of them have been about company updates and 3 about people movement.